Dabrafenib (Tafinlar) -

Dabrafenib (Tafinlar)
Information type: Drug best practice guidance
Source: Scottish Medicines Consortium
Specialities: Cancers
Summary
The SMC has accepted dabrafenib as monotherapy in adults with unresectable or metastatic BRAFV600 mutation-positive metastatic melanoma who have received no prior therapy, based on availability via the Patient Access Scheme (PAS) that improves the cost-effectiveness of the drug.
UKMi comment
NICE also recommends, within its marketing authorisation, dabrafenib as an option for treating unresectable or metastatic BRAF V600 mutation positive melanoma only if the company provides dabrafenib with the discount agreed in the patient access scheme.
Related links: NICE guidance for dabrafenib (October 2014)